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Summary New therapeutic strategies are now being developed against adenocarcinoma associated with erbB-2amplification, particularly by
inhibiting p185erbB-2 expression. Antisense oligodeoxynucleotides seem promising for this purpose as long as they are efficiently protected
against degradation and targeted into the cells. We present antisense oligonucleotide carriers, the supramolecular biovectors (SMBVs), for
which we have already demonstrated the ability to improve both cellular uptake and protection of oligodeoxynucleotide. The present work
demonstrates that SMBVs elicit a specific and non-toxic action of antisense compounds in a cell model, irrespective of their sensitivity to
nucleases. This is a major point, considering the specificity problems associated with the use of nuclease-resistant phosphorothioate
oligodeoxynucleotide. SMBVs improve antisense efficiency of oligodeoxynucleotide designed against p185erB-2, with a complete growth
arrest of SK-Br-3, human adenocarcinoma mammary cells that overexpress p18ertB-2 and no effect on MCF-7 cells that normally express
p185ertB-2. The comparison of SMBVs with DOTAP reveals the statistically higherefficiency of SMBVs, which allows the antisense inhibition of
p185erbB-2 expression in 65-75% of SK-Br-3 cells (P< 0.05). The efficiency and controlled synthesis of SMBVs underline their potentialities as
oligodeoxynucleotide carriers for in vivo experiments.
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The erbB-2 proto-oncogene encodes a 185-kDa transmembrane
tyrosine kinase growth factor receptor, the protein p185erbB-2 (King
et al, 1985). Overexpression of Pl85erbB-2 is strongly correlated
with the development ofa number ofhuman adenocarcinomas and
results from gene amplification and/or transcriptional deregula-
tion. This overexpression is associated with around 30% ofbreast
and ovarian tumours (Dougall et al, 1994), in which it has been
correlated with short time to relapse and poor patient survival
(Slamon et al, 1987; Yu et al, 1994).
New therapeutic strategies of the various adenocarcinomas
associated with erbB-2 amplification have been developed, which
inhibit either P185erbB-2 function or P185erbB-2 expression. The
former case is based on the use of monoclonal antibodies,
immunotoxins and tyrosine kinase inhibitors (Stancovski et al,
1991; Bacus et al, 1992; Beerli et al, 1995; King et al, 1996).
Monoclonal antibodies specific for the extracellular domain of
P185erbB-2 can inhibit erbB-2-dependent tumour growth but can
also act as receptor agonists (Stancovski et al, 1991). Moreover,
such treatments are equally efficient for both cell types without
discriminating between cells that express elevated amounts of
P185erbB-2 and those that show low levels (Bacus et al, 1992). A
challenging approach consists of the use of antisense
oligodeoxynucleotides (ODNs), in the inhibition of P185erbB-2
expression, designed to hybridize to erbB-2 mRNA. Such anti-
sense ODNs inhibit P1 85erbB-2 expression in vitro and, in turn, cell
proliferation (Bertram et al, 1994; Brysch et al, 1994; Colomer
et al, 1994; Vaughn et al, 1995; Wiechen and Dietel, 1995).
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A comparative study outlined the superiority ofthe inhibition by
antisense ODN: whereas the inhibitory activity of a monoclonal
antibody or a tyrosine kinase inhibitor only lasted a few hours,
antisense ODN inhibition could be detected over several days
(Wiechen and Dietel, 1995). Nevertheless, the use ofODNs is still
limited by two major drawbacks: their poor diffusion through
plasma membranes and their rapid degradation by nucleases
(Helene and Toulme, 1990). The antisense inhibition of PI85ebB-2
in SK-Br-3 cells, a human mammary adenocarcinoma cell model
overexpressing the transmembrane receptor, has thus necessitated
the use of either native phosphodiester ODNs at a very high
concentration (Colomer et al, 1994) or nuclease-resistant
phosphorothioate ODNs, carried by commercialized cationic lipids
or not (Bertram et al, 1994; Brysch et al, 1994; Vaughn et al, 1995).
Because the evidence is becoming stronger for the non-sequence-
specific effects ofphosphorothioate ODN (Stein and Cheng, 1993;
Gura, 1995; Stein, 1995), the development of ODN carriers would
seem necessary to improve both the transport and the stability of
native ODNs, while preserving their target specificity. Synthetic
commercialized cationic lipids, such as DOTMA or DOTAP
(Capaccioli et al, 1993; Dean and Mckay, 1994), or synthetic
carriers such as nanoparticles (Schwab et al, 1994) are widely used
because oftheirefficiency in enhancing antisense ODN uptake into
cells and decreasing their degradation. These ODN carriers are
promising for in vitro experiments and local administration, but
their instability and the cellular toxicity of these complexes limit
their use for in vivo systemic administration (Lewis et al, 1996).
The SupraMolecular BioVectors (SMBVs) are new potential anti-
senseODNcarriers. These are multilayeredparticles composedofan
internal ionic polysaccharide core surrounded by alipid layer(Peyrot
et al, 1994; Samain et al, 1994). By modulating the charge of the
internal core, various molecules, such as interleukin 2 (Castignolles
et al, 1994) or gentamycin and doxorubicin (De Miguel et al, 1995),
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have been efficiently incorporated into SMBVs. The limitation of
their size to around 30 nm diameter means that ahigh diffusibility of
the carriers, not only into tissues and organs but also within cells, can
be predicted. SMBVs characterized by cationic cores have been
developed and proved to incorporate anionic ODNs efficiently and
stably (Berton et al, 1997). We have already reported that SMBVs
bring about a significant increase in cellular ODN uptake and protec-
tion (Berton et al, 1997).
The aim of the present work was to evaluate the ability of
SMBVs to improve the antisense effect of both phosphorothioate
and phosphodiester ODNs, designed to inhibit erbB-2 mRNA
translation, in two cell models overexpressing P185erbB-2 or not.
The antisense effect was proved by analysis ofthe protein expres-
sion and the proliferation, in comparison with DOTAP, a well-
known, commercialized antisense ODN carrier.
MATERIAL AND METHODS
Antisense oligodeoxynucleotides
We used 15-mer oligodeoxynucleotides (ODNs) with a sequence
complementary to the AUG initiation codon of erbB-2 mRNA
(5'CTC CAT GGT GCT CAC-3') and the scrambled sequence (5'-
CGC CTT ATC CGTAGC-3'). They were either phosphodiester or
phosphorothioate ODNs according to the experiments, as specified
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in Results. All ODNs were synthesized and high-performance
liquid chromatography (HPLC) purified by Genset (France).
Cell culture
The human adenocarcinoma breast cell lines SK-Br-3, MCF-7,
MDA-MB-468 were obtained from the American Tissue Culture
Collection. SK-Br-3 cells exhibit a four- to eightfold amplification
of the erbB-2 gene, associated with elevated amounts of erbB-2
mRNA and with an overexpression of P185erbB-2, while MCF-7
cells show low levels and MDA-MB-468 cells do not express
P185erbB-2 (Kraus et al, 1987). SK-Br-3 and MCF-7 were grown
routinely in RPMI-1640 growth medium (Gibco, France) and
MDA-MB-468 in Dulbecco's modified Eagle medium (DMEM)
growth medium (Gibco), supplemented with 5% fetal bovine
serum (FBS) (Gibco) and containing 4.5 g -1 glucose. Cells were
incubated at 37°C in a humidified 5% CO2 incubator.
Incorporation of ODNs into SMBVs
As described previously (Berton et al, 1997), ODN solution in
water was slowly added to SMBV suspension (I mg of polysac-
charide core ml-'; Biovector Therapeutics, France) and incubated
at45°C with magnetic stirring for 5 h. The incorporation yield was
100% with an initial incorporation ratio of 10% (w/w).
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Figure 1 Dot-plot representation of flow cytometry analysis of SK-Br-3 cells (A and D), MCF-7 cells (B and E) and MDA-MB-468 cells (C). Control cells (A, B
and C) are compared with cells treated by phosphorothioate antisense ODNs at a 4gM concentration, incorporated into SMBVs 72 h before (D and E). Red
fluorescence intensities or FL2 (y-axis) measure phycoerythrin secondary antibody for p185ebB-2 protein detection, while the forward scattering or FSC (x-axis)
indicates the size of each cell analysed. The highest threshold value, drawn horizontally, is set at 200 arbitrary units (AU) and the lowest at 10 arbitrary units
(AU). Dot-plots are obtained by the analysis of 104 cells
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Figure 2 Histogram representation of flow cytometry analysis of SK-Br-3
cells (A) and MCF-7 cells (B) 72 h after phosphorothioate ODN treatments.
Percentages of cells exhibiting p1 85ebB-2 protein at lower (dark dashes) and
at higher (light dashes) levels than the threshold values (200 and 10 arbitrary
units) are presented. Cells were treated with SMBV-incorporated ODN, with
ODN-DOTAP complexes or with free ODNs. Antisense (ASO) and scrambled
(SC) ODN sequences were compared at a final concentration of 4 gim. Error
bars indicate mean percentage of cells ± standard deviation from four and
two experiments (for SK-Br-3 and MCF-7 cells respectively). In one set of
experiments (A or B), the results obtained with ODNs incorporated into
SMBVs were statistically different from those obtained with ODNs associated
with DOTAP (*P < 0.05)
Mannheim, France) of 82 jig ml-' was used. For this, an ODN-
DOTAP complex (respectively 30.4 and 136.7 jig ml-') was first
prepared in Hepes buffer (20 mmv Hepes, pH 7.4). An aliquot of
180 gil of this complex was added to 120 gil offreshly trypsinized
cell suspension (containing 7 x 10- cells) in culture medium
without FBS. After a 4 h incubation at 370C, 1 ml of culture
medium containing 5% FBS was added to the cells.
Optimal ODN incubation times for each of the two delivery
systems have been set according to previously obtained data. We
have shown that a 5-h incubation of SMBV-ODN with cells was
optimal to obtain maximum cumulative ODN uptake (Berton et al,
1997). According to the supplier's recommendations, a minimal 3-
h incubation of DOTAP-ODN complex with cells allows optimal
ODN uptake, and lipofection of SK-Br-3 cells has been shown to
be optimal after a 4-h incubation with ODN-cationic lipid
complex (Vaughn et al, 1995).
In agreement with the long half-life time of P185erbB-2 (> 12 h;
Vaughn et al, 1995), we determined that 72 h was the optimal lag
time for the analysis of P185erbB-2 downregulation (data not
shown). -We checked that, at the SMBV concentration used
(180jig ml-1), more than 70% of SK-Br-3 cells were viable [meta-
bolic activity by MTT test as described previously (Berton et al,
1997)] after 72 h, thus indicating the low toxicity ofthe carrier.
p1 85erbB-2 expression analysis
This analysis was performed as described previously (Vaughn et
al, 1995). Briefly, 7 x 104 cells were seeded per well in 24-well
plates and treated, as described above, in a final volume of 300pl.
After 72 h, the culture medium was removed, and the cells were
collected by trypsinization, washed three times with ice-cold wash
buffer (0.5% FBS and 0.1% sodium azide in PBS), then resus-
pended in 100 jil of an ice-cold phosphate-buffered saline (PBS)
solution containing 0.1% bovine serum albumin (BSA), 0.1%
sodium azide and 0.25 jig ml-1 erbB-2 mouse monoclonal anti-
body (0P39; Oncogene Science, France). Cells were incubated at
40C for 1 h, washed three times in wash buffer and resuspended in
50 jil of an ice-cold PBS solution containing 0.1I% BSA, 0.1I%
sodium azide and 10jig ml-' phycoerythrin-labelled goat anti-
mouse conjugate (Molecular Probes, France). Cells were incu-
bated at 40C for 1 h, washed twice in wash buffer and analysed by
flow cytometry (FACS-scan; Becton Dickinson, France) with a
488-nm laser excitation and a 585-nm emission filter (FL2 emis-
sion). Data were obtained from 10"viable cells.
Cell treatment conditions
Control cells were compared with cells treated either with free
ODN (antisense or scrambled sequence), with ODN-DOTAP
complexes or with SMBV-incorporated ODNs. The optimal treat-
ment conditions selected were as follows: cells were incubated with
phosphorothioate ODN (incorporated into SMBVs or extemporally
associated with DOTAP) at a 4 jim concentration (1 8 jig ml-') in
culture medium without FBS.
For SMBV treatments, ODNs containing SMBV at mg of
polysaccharidic core ml in water were diluted to 180 jig ml in
300 jil of freshly trypsinized cell suspension (containing 7 x 104
cells) in culture medium without FBS. After a 5-h incubation, ml
of culture medium containing 5% FBS was added to the cells.
To maintain a DOTAP-ODN weight ratio of 4.5, as described
by the supplier, a final concentration of DOTAP (Boehringer
Cell proliferation experiments
Approximately 3500 cells were seeded per well in 96-well plates
and treated under various conditions, as described above, in a final
volume of 60 jil and incubated at 370C. At various times, cells
were collected by trypsinization and counted in a cell counter
(Coultronics, France). Six independent wells were counted for
each time point and the results were averaged.
Statistical analysis
After the homogeneity of variances had been checked (Hartley
test), a one-way analysis of variance (ANOVA) was performed.
The Scheff test was used as a post hoc test for intertreatment
comparisons.
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Figure 3 Proliferation rates of SK-Br-3 cells (A and B) and MCF-7 cells (C
and D). Cells were treated either with SMBV-incorporated ODNs (A and C) or
with ODN-DOTAP complexes (B and D). Phosphorothioate antisense (ASO)
and phosphorothioate scrambled (SC) ODN sequences were compared at a
final concentration of 4gm. Error bars indicate the mean number of cells per
well ± standard deviation from six wells
RESULTS
p185e8bB-2 expression analysis
Control SK-Br-3 cells exhibit a pl85erbB-2 expression level (FL2)
of around 950 arbitrary units (Figure IA). Statistical analysis of
this dot-plot indicates that 94% of cells have a pl85erbB-2 expres-
sion level superior to 200 arbitrary units, the highest threshold
value drawn horizontally on the dot-plot. The control MCF-7 cells,
which display a normal low expression of p185erbB-2 (Kraus et al,
1987), exhibit a lower mean fluorescence intensity, around 50
arbitrary units (Figure iB). As expected, the MDA-MB-468 cells
(not expressing p1 85erbB-2; Kraus et al, 1987) show a background
level of pl85erbB-2, with a mean fluorescence intensity around 2
arbitrary units (Figure IC).
A dramatic change in the dot-plot is observed for the SK-Br-3
cells treated with antisense phosphorothioate ODNs incorporated
into SMBVs (Figure ID). Some 65% ofcells are shifted to a lower
pl85erbB-2 expression level. The treatment of MCF-7 cells by anti-
sense phosphorothioate ODNs incorporated into SMBVs does not
lead to such impressive changes as in SK-Br-3 cells (Figure 1E). A
lower threshold value was set horizontally on the dot-plot, in such
a way that 94% of control cells had a higher pl85erbB-2 expression
level. Only a few cells exhibited a lower fluorescence intensity
than this second threshold value (10 arbitrary units).
The results, expressed as percentages of cells exhibiting
p185erbB-2 at lower or at higher levels than the threshold values, are
summarized in Figure 2. Results obtained with SK-Br-3 cells
(Figure 2A) confirm that a significantly higher percentage ofcells
(65%) expresses a lower level of pl85erbB-2 than the control cells,
when antisense phosphorothioate ODNs are incorporated into
SMBVs (P < 0.001). The treatment ofcells with empty SMBVs or
with SMBVs containing scrambled phosphorothioate ODNs does
not induce any significant change in the 94% of cells over-
expressing p185erbB-2. This demonstrates that the downregulation
of pl85erbB-2 expression (with a fluorescence mean intensity
shifting from 950 to 50 arbitrary units) is caused by a specific
action of antisense phosphorothioate ODNs. Treatment of cells
with antisense ODN-DOTAP complexes leads to a decreased
level ofpl85erbB-2 in 40% of cells. This antisense effect is statisti-
cally lower than that driven by SMBVs (P < 0.05).
Only 13% ofthe MCF-7 cells (Figure 2B) display a lower level
of pl85erbB-2 expression when treated with antisense ODNS
incorporated into SMBVs. This result is statistically different
from the 6% obtained under control conditions (P < 0.05), but
use ofthe antisense ODN-DOTAP complex leads to similar inhi-
bition (16.5%).
The incubation of both SK-Br-3 and MCF-7 cells with free
phosphorothioate ODNs does not induce any antisense effect at
the protein level (Figure 2A and B).
Cell proliferation inhibition
The SK-Br-3 cell growth kinetics demonstrate that antisense
phosphorothioate ODNs, whether incorporated into SMBVs
(Figure 3A) or associated with DOTAP (Figure 3B), induce a
complete inhibition of cell growth during the 120 h after treat-
ment. Nevertheless, it should be noted thatDOTAP (free or associ-
ated with scrambled ODN) totally blocks cell growth for 72 h,
whereas little alteration in cell growth is obtained with SMBVs
alone. The incubation of cells with free phosphorothioate ODNs
does not induce any antisense effect, tested in terms ofcell prolif-
eration (data not shown).
In the case of MCF-7 cells (Figure 3C and D), antisense phos-
phorothioate ODNs, whetherincorporated into SMBVs (Figure 3C)
or associated with DOTAP (Figure 3D), do not induce the complete
arrest of cell growth observed in SK-Br-3 cells. Slight toxicity is
observed with both carriers but is not distinguishable from the
growth inhibition caused by either antisense or scrambled ODNs.
Nuclease-sensitive phosphodiester ODNs
The comparison of SK-Br-3 cells treated with phosphodiester
(Figure 4) and phosphothioate (Figure 2A) ODNs reveals similar
behaviour. The cells display a decreased level of p185erbB-2 after
incubation with antisense phosphodiester ODNs incorporated into
SMBVs (74%) or associated with DOTAP (45%). SMBVs thus
clearly elicit a higher inhibition by antisense ODNs than DOTAP
(P < 0.05). Control experiments using scrambled phosphodiester
ODNs have demonstrated that the downregulation of pl85e6B-2
expression is the result of a specific action of antisense phospho-
diester ODNs.
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Figure 4 Histogram representation of flow cytometry analysis of SK-Br-3
cells 72 h after phosphodiester ODN treatments. Percentages of cells
exhibiting p185erB-2 protein at lower (dark dashes) and higher (light dashes)
levels than the threshold values (200 arbitrary units) are presented. Cells
were treated with SMBV-incorporated ODNs, with ODN-DOTAP complexes
or with free ODNs. Antisense (ASO) and scrambled (SC) ODN sequences
were compared at a final concentration of 4gM. Error bars indicate the mean
percentage of cells ± standard deviation from four experiments. Results
obtained with ODNs incorporated into SMBVs were statistically different from
those obtained with ODNs associated with DOTAP (*P < 0.05)
DISCUSSION
The development ofnew synthetic antisense ODN carriers is crucial
for systemic administrations and clinical trials because of the
instability and cellular toxicity of current ODN carriers, such as
ODN-cationic lipid complexes (Lewis et al, 1996). The present
work clearly demonstrates the ability of SMBVs, a non-toxic
synthetic ODN carrier, to elicit the complete cell growth arrest of
pl85erbB-2-overexpressing cells by antisense ODN. This blockage
results from a dramatic inhibition ofp185ebB-2 expression, which is
significantly higherthan thatinduced by ODN-DOTAP complexes.
Moreover, this work underlines the fact that native phosphodiester
ODNs, when associated with SMBVs, are as efficient as phospho-
rothioate ODNs in inhibiting pl85erbB-2 expression, thus circum-
venting the specificity problems associated with the latter.
In aprevious work, we showed thatSMBVs significantly increase
ODN uptake in the cell cytosolic fraction (Berton et al, 1997), which
should lead to an improved effect of phosphorothioate ODNs. As
expected, a specific inhibition ofpl85erbB-2 expression is observed in
SK-Br-3 cells, whereas free ODNs have no effect. Moreover, a
significantly higher percentage of cells shows an inhibition of
plret,B-2 expression when the ODNs are carried by SMBVs (65%)
rather than by DOTAP (40%). In both cases, a complete and anti-
sense-specific growth arrest ofSK-Br-3 cells is obtained.
It is noteworthy that SMBVs alone only slow down SK-Br-3
cell growth under these conditions (more than 70% of SK-Br-3
cells viable after 72 h), whereas DOTAP induces a complete and
non-specific growth arrest during the first 72 h after the treatment.
This phenomenom can be caused by toxicity, detachment or other
mechanisms that we have not identified. It is only after 96 h that a
specific antisense inhibition of cell growth can be distinguished
from the intrinsic toxicity of the DOTAP. In contrast, neither
SMBVs nor DOTAP are toxic to MCF-7 cells under the same
treatment conditions. A sensitivity to carriers that is dependent on
the cell type is thus apparent. The non-sequence-specific effects of
phosphorothioate antisense ODNs strongly restrict their possibili-
ties for clinical trials (Stein and Cheng, 1993; Gura, 1995; Stein,
1995). In our previous work, it was demonstrated that incorpora-
tion into SMBVs increases the half-life time of phosphodiester
ODNs 11-fold in cell growth medium (Berton et al, 1997).
Furthermore, a high proportion ofODNs present in the cell cytosol
was shown to remain intact if incorporated into SMBVs, whereas
free ODNs were completely degraded (Berton et al, 1997). Indeed,
other studies estimated that free DNA ODN half-life time is
around 30 min in cytosol (Fisher et al, 1993). Comparison of the
ability of SMBVs to improve the antisense effect of phospho-
diester and phosphorothioate ODNs was thus a key point. We
confirm here that native and nuclease-resistant ODNs have a
similar antisense effect with regard to pl85e6B-2 expression when
incorporated into SMBVs. This result demonstrates that the incor-
poration of ODNs into SMBVs allows their long-term protection,
suggesting that SMBVs do not degrade immediately after entry
into cells. Again, a specific inhibition of pl85erbB-2 expression is
observed in a significantly higher percentage of SK-Br-3 cells,
using phosphodiester ODNs carried by SMBVs (74%) than with
phosphodiester ODNs carried by DOTAP (45%). This demon-
strates that SMBVs are efficient native ODN carriers at the cellular
level as regards improved ODN uptake and protection.
A differential antisense effect ofODNs in cells that overexpress
or normally express a protein is of major interest in obtaining
selective growth inhibition of tumoral cells characterized by a
gene amplification (e.g. myc and erbB-2). It has already been
shown that the preferential accumulation and retention ofantisense
ODNs in cells correlate with the number of target mRNA copies
(Dewanjee et al, 1994; Urbain et al, 1995). We have shown that
p185erbB-2 overexpression in SK-Br-3 cells (950 arbitrary units) is
decreased 19-fold by ODNs incorporated into SMBVs to the
normal expression level observed in control MCF-7 cells (50 arbi-
trary units). Besides, only 13% of MCF-7 cells have the pl85erbB-2
expression lowered 12.5-fold to close to the background level of
the MDA-MB-468 cells (4 arbitrary units), known not to express
pl85erIB-2 (Kraus et al, 1987). As it has been proved that SMBVs
efficiently enter MCF-7 cells (Berton et al, 1997), these results
suggest that ODNs incorporated into SMBVs have access or
hybridize to target mRNA more efficiently in pl85erbB-2-over-
expressing cells than in those normally expressing p185erbB-2. The
abundance and/or accessibility ofmRNA in the cytoplasm ofcells
overexpressing a protein would be the preferential target for
antisense ODNs incorporated into SMBVs (Xing et al, 1993;
Dewanjee et al, 1994; Urbain et al, 1995). This hypothesis has to
be demonstrated now on various cell lines in order to eliminate
the possibility of antisense and lipid variability effects among
different cell lines. Indeed, a difference in degradation or elimina-
tion of ODNs among MCF-7 and SK-Br-3 cells may exist.
In this report, the use of SMBVs as ODN carriers is shown to
elicit a specific, non-toxic action of antisense ODNs, irrespective
of their nuclease sensitivity. The synthesis of SMBVs can be
perfectly controlled and modulated (lipid composition, particle
charge and size) to allow optimal stability of the ODN-SMBV
complexes in physiological conditions and possible cell targeting.
SMBVs are thus revealed to be promising antisense ODN carriers,
the development of new phosphodiester ODN carriers for clinical
purposes being a crucial issue (Lewis et al, 1996).
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